Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial

Title: Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial
Authors: Gupta, V.; Oh, S.; Devos, T.; Dubruille, V.; Catalano, J.; Somervaille, Tim C P; Platzbecker, U.; Giraldo, P.; Kosugi, H.; Sacha, T.; Mayer, J.; Illes, A.; Ellis, C.; Wang, Z. H.; Carreras, F. J. G.; Strouse, B.; Mesa, R.
Contributors: The Christie NHS Foundation Trust & Cancer Research UK Manchester Institute, Manchester, UK.
Publication Year: 2024
Collection: The Christie School of Oncology: Christie Research Publications Repository
Description: A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, we performed a descriptive post hoc exploratory analysis of the double-blind, randomized, phase 3 SIMPLIFY-1 study (NCT01969838; N = 432, JAK inhibitor naive, momelotinib vs. ruxolitinib); subgroups were defined by baseline hemoglobin: = 10 to = 12 g/dL (nonanemic). Spleen and symptom results were generally consistent with those previously reported for the intent-to-treat population. In anemic subgroups, momelotinib was associated with higher rates of transfusion independence and reduced/stable transfusion intensity vs. ruxolitinib. No new or unexpected safety signals were identified. Overall, momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. ruxolitinib in patients with hemoglobin
Document Type: article in journal/newspaper
Language: English
Relation: https://dx.doi.org/10.1080/10428194.2024.2328800; http://hdl.handle.net/10541/626928; Leukemia & Lymphoma
DOI: 10.1080/10428194.2024.2328800
Availability: http://hdl.handle.net/10541/626928; https://doi.org/10.1080/10428194.2024.2328800
Accession Number: edsbas.F3E2DA76
Database: BASE